We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Continuous Glucose Monitoring Sensors Compared for Effectiveness

By LabMedica International staff writers
Posted on 01 Oct 2014
A continuous glucose monitor, a tool used in optimizing glycemic control in patients with type 1 diabetes, is a subcutaneous tissue sensor that provides an interstitial fluid glucose measurement every one to five minutes.

The simultaneous use of two popular continuous glucose monitoring (CGM) sensors revealed clear differences in their accuracy and in patient-rated treatment experiences, including ease of use, feelings of safety, and willingness to use the system in daily life.

Scientists at the University of Gothenburg (Sweden) working with their North American colleagues enrolled 38 patients who met the inclusion criteria for the study. More...
The mean age was 50 years, 66% were men, and mean diabetes duration was 22.9 years. The mean HbA1c level was 58.9 mmol/mol or 7.5%. Patients were educated on how to use the CGM sensors, and the sensors were calibrated. All participants were educated on use of the HemoCue (Ängelholm, Sweden) analyzer and cuvettes and were advised to measure capillary glucose values six to 10 times per day.

The 38 ambulatory patients with type 1 diabetes used the Dexcom G4 PLATINUM (San Diego, CA, USA) and the Enlite Guardian REAL-Time System (Medtronic MiniMed, Inc.; Northridge, CA, USA) CGM sensors simultaneously for a minimum of four and maximum of six days. The mean absolute relative difference (MARD) in blood glucose for the Dexcom G4 was significantly lower (13.9%) than for the Enlite sensor (17.8%) among a total of 1,012 sets of measurements. For glucose levels in the hypoglycemic range of less than 4.0 mmol/L, the MARD for the Dexcom G4 was 20.0% compared with 34.7% for the Enlite. More patients rated their experience with the Dexcom G4 as positive and preferred to use it in their daily lives.

The authors concluded that the Dexcom G4 CGM system showed greater accuracy than the Enlite system, and patients had a significantly more positive treatment experience. The findings indicate that the Dexcom G4 is more optimal when dosing insulin, when taking other treatment actions, and in avoiding hypoglycemia. The results also indicate that the Dexcom G4 may make it possible for more patients to wear a CGM device for a longer period of time. These findings should be considered by treatment providers when recommending suitable CGM systems and evaluating ongoing therapies. The study was published on September 18, 2014, in the journal Diabetes Technology & Therapeutics.

Related Links:

University of Gothenburg
HemoCue
Dexcom



New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Mini Vortex Mixer
Vornado
New
Automated Microscope
dIFine
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Schematic overview of the deep learning-based circulating exosome analysis for lung cancer detection (Photo courtesy of Chuan Xu, Cheng Jiang)

Liquid Biopsy Approach to Transform Diagnosis, Monitoring and Treatment of Lung Cancer

Lung cancer continues to be a major contributor to cancer-related deaths globally, with its biological complexity and diverse regulatory processes making diagnosis and treatment particularly difficult.... Read more

Pathology

view channel
Image: The Aiforia Breast Cancer Grading AI solution is CE-IVD marked (Photo courtesy of Aiforia Technologies)

Clinical AI Solution for Automatic Breast Cancer Grading Improves Diagnostic Accuracy

Labs that use traditional image analysis methods often suffer from bottlenecks and delays. By digitizing their pathology practices, labs can streamline their work, allowing them to take on larger caseloads... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.